Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 907828 plus ezabenlimab in TP53 wild-type advanced solid tumors
NL-OMON53927Phase 1Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brigimadlin and ezabenlimab in Nonhematologic neoplasms, soft tissue sarcoma (STS), non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Objective response by RECIST 1.1 and Progression-free survival. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
brigimadlinezabenlimab
03
Conditions
Nonhematologic neoplasmssoft tissue sarcoma (STS)non-small cell lung cancer (NSCLC)gastric adenocarcinomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON53927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53927.